Stryker Co. (NYSE:SYK) Shares Acquired by GLOBALT Investments LLC GA

GLOBALT Investments LLC GA raised its stake in Stryker Co. (NYSE:SYK) by 27.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,885 shares of the medical technology company’s stock after acquiring an additional 4,013 shares during the period. GLOBALT Investments LLC GA’s holdings in Stryker were worth $6,800,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. GWN Securities Inc. acquired a new position in Stryker in the fourth quarter valued at approximately $231,000. Glenview Trust co boosted its stake in Stryker by 0.8% in the fourth quarter. Glenview Trust co now owns 4,382 shares of the medical technology company’s stock valued at $1,578,000 after acquiring an additional 33 shares during the period. Harbour Investments Inc. boosted its stake in Stryker by 17.4% in the fourth quarter. Harbour Investments Inc. now owns 7,431 shares of the medical technology company’s stock valued at $2,676,000 after acquiring an additional 1,101 shares during the period. Corient Private Wealth LLC boosted its stake in Stryker by 1.1% in the fourth quarter. Corient Private Wealth LLC now owns 1,097,038 shares of the medical technology company’s stock valued at $394,990,000 after acquiring an additional 11,889 shares during the period. Finally, Pollock Investment Advisors LLC acquired a new position in Stryker in the fourth quarter valued at approximately $1,134,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

NYSE SYK opened at $369.96 on Monday. The stock has a market capitalization of $141.17 billion, a P/E ratio of 47.68, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The business’s fifty day moving average is $383.04 and its two-hundred day moving average is $373.60. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 EPS. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on SYK shares. Truist Financial boosted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Citigroup reiterated a “buy” rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 price objective on Stryker in a research report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.